A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen - Full Text View

Sponsor:	Kirby Institute
Collaborators:	Merck Abbott American Foundation for AIDS Research
Information provided by (Responsible Party):	Kirby Institute
ClinicalTrials.gov Identifier:	NCT00931463

Purpose

The investigators hypothesize that following virological failure of a standard NNRTI+2N(T)RTI regimen second-line antiretroviral therapy consisting of ritonavir-boosted lopinavir and 2N(T)RTIs will offer comparable efficacy to that provided by ritonavir-boosted lopinavir and raltegravir.

The study will be conducted for 96-weeks with the primary endpoint analyzed after 48-weeks.

The primary endpoint is virological: a comparison of virological suppression in plasma < 200 copies/mL between the randomized arms after 48 weeks.

Secondary and exploratory endpoints include virological, immunological, safety, clinical, metabolic, drug adherence, drug resistance and quality of life.

Condition	Intervention	Phase
HIV Infections	Drug: Ritonavir-boosted lopinavir and raltegravir Drug: Ritonavir-boosted lopinavir and 2N(t)RTI	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Randomised Open-label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-line NNRTI/2N(t)RTI Therapy

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: HIV/AIDS

Drug Information available for: Ritonavir Lopinavir Raltegravir Raltegravir potassium

U.S. FDA Resources

Further study details as provided by Kirby Institute:

Primary Outcome Measures:

The primary outcome measure of this study is a comparison of the virological efficacy of the two strategies as measured by the proportion of participants with HIV RNA < 200 copies/mL 48 weeks after randomization. [ Time Frame: 48 weeks following randomization ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

A number of secondary outcome measures will be examined in this protocol by randomised treatment arm including virological, immunological, safety and antiretroviral therapy endpoints. Exploratory endpoints include clinical, metabolic, drug resistance. [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	550
Study Start Date:	September 2009
Estimated Study Completion Date:	August 2013
Estimated Primary Completion Date:	September 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Ritonavir-boosted lopinavir and 2N(t)RTI This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.	Drug: Ritonavir-boosted lopinavir and 2N(t)RTI Ritonavir-boosted lopinavir 2 heat-stable tablets taken every 12 hours and 2N(t)RTIs as prescribed Other Name: nucleosides, nucleotides, nuncleoside backbone
Experimental: Ritonavir-boosted lopinavir and raltegravir This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.	Drug: Ritonavir-boosted lopinavir and raltegravir Two heat-stable ritonavir-boosted lopinavir tablets and one 400 mg raltegravir tablet taken every 12 hours Other Name: Kaletra, Aluvia, Isentress

Detailed Description:

In HIV-infected subjects who have virologically failed first-line antiretroviral therapy comprising 2N(t)RTI + NNRTI a regimen of second-line therapy incorporating ritonavir-boosted lopinavir and raltegravir provides comparable (i.e., non-inferior) antiretroviral efficacy over 48 weeks to a regimen containing ritonavir-boosted lopinavir and 2-3N(t)RTIs.

Eligible patients will be randomised to one of two arms:

I. ritonavir boosted lopinavir (LPV/r) 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3N(t)RTIs

II. ritonavir boosted lopinavir (LPV/r) 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400 mg twice daily

The primary objective of this study is to compare the virological efficacy of the two strategies as measured by the proportion of participants with HIV RNA < 200 copies/mL 48 weeks after randomisation.

Secondary objectives include virological, immunological, safety and antiretroviral therapy endpoints.

Exploratory endpoints include clinical, metabolic, drug resistance, medication adherence and quality of life endpoints.

Eligibility

Ages Eligible for Study:	16 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV-1 positive by licensed diagnostic test
Aged 16 years or older (or minimum age as determined by local regulations or as legal requirements dictate)
Have received first antiretroviral regimen consisting of an NNRTI plus 2N(t)RTIs for at least 24 weeks
No change in antiretroviral therapy within 12 weeks prior to screening
Failed first-line NNRTI + 2N(t)RTI combination therapy according to virological criteria defined by two consecutive (at least 7 days apart) HIV RNA results of greater then 500 copies/mL
No prior or current exposure to HIV protease inhibitors and/or HIV integrase inhibitors
Able to provide written informed consent

Exclusion Criteria:

The following laboratory variables:
- absolute neutrophil count (ANC) < 500 cells/microlitres
- hemoglobin < 7.0 g/decilitres
- platelet count < 50,000 cells/microlitres
- ALT great than 5 x ULN
Pregnant or nursing mothers
Participants with active viral hepatitis B infection defined by the presence in serum of hepatitis B surface antigen
Use of immunomodulators within 30 days prior to screening
Use of any prohibited medications (rifampicin, midazolam, triazolam, cisapride, pimozide, amiodarone, dihydroergotamine, ergotamine, ergonovine, methylergonovine, astemizole, terfenadine, vardenafil, and St. John's wort)
Intercurrent illness requiring hospitalization
Active opportunistic disease not under adequate control in the opinion of the site Principal Investigator
Participants with current alcohol or illicit substance abuse that in the opinion of the site Principal Investigator might adversely affect participation in the study
Participants deemed by the site Principal Investigator unlikely to be able to remain in follow-up for the protocol-defined period

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00931463

Show 44 Study Locations

Sponsors and Collaborators

Kirby Institute

Merck

Abbott

American Foundation for AIDS Research

Investigators

Study Chair:	David A Cooper, MD	Kirby Institute
Study Chair:	Brian Gazzard, MD	St. Stephen's Trust
Study Director:	Mark A Boyd, MD	Kirby Institute

More Information

No publications provided

Responsible Party:	Kirby Institute
ClinicalTrials.gov Identifier:	NCT00931463 History of Changes
Other Study ID Numbers:	SECOND-LINE
Study First Received:	July 1, 2009
Last Updated:	August 29, 2011
Health Authority:	Australia: Department of Health and Ageing Therapeutic Goods Administration; European Union: European Medicines Agency; Malaysia: Ministry of Health; Nigeria: The National Agency for Food and Drug Administration and Control; Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica; Argentina: Human Research Bioethics Committee; Argentina: Ministry of Health; Chile: Comisión Nacional de Investigación Científica y Tecnológica; Chile: Instituto de Salud Publica de Chile; Mexico: Ethics Committee; Mexico: Federal Commission for Protection Against Health Risks; Peru: Ethics Committee; Peru: Ministry of Health

Keywords provided by Kirby Institute:

second line therapy
combination antiretroviral therapy
first-line failure
AIDS
treatment experienced

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Reverse Transcriptase Inhibitors
Ritonavir

Lopinavir
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
HIV Protease Inhibitors
Protease Inhibitors
Anti-HIV Agents

ClinicalTrials.gov processed this record on February 09, 2012